Skip to content
zameds

Colchicine (Colnova)

Colchicine

Novagen Pharma (Pty) Ltd

Every registration of this product has been cancelled.

Registration

Applicant
Novagen Pharma (Pty) Ltd
Certificate holder
Novagen Pharma (Pty) Ltd
Registrations
1

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Colnova 0,5

EACH TABLET CONTAINS COLCHICINE 0,5 mg

0,5 mgTablet55078455/3.3/0784Approved 4 April 2023CancelledNot determinedPIPIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S3: Colchicine

    • except when intended for the emergency treatment of acute gout, subject to a maximum total treatment course of 6 milligrams. (S2)

    Consolidated Schedules 06 July 2026, lines 3374 to 3375

  • S2: Colchicine

    • when intended for the emergency treatment of acute gout, subject to a maximum total treatment course of 6 milligrams. (S3)

    Consolidated Schedules 06 July 2026, lines 1780 to 1781

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C22H25NO6399.40 g/mol

N-[(7S)-1,2,3,10-Tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide

Drag to rotate. Structure from PubChem CID 6167.

SAHPRA documents

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles